These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30310501)

  • 1. Weekly versus triweekly cisplatin plus intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: A propensity score analysis with a large cohort.
    Zhu Q; Hu H; Tang LQ; You R; Zhao JJ; Weng DS; Pan QZ; Chen CL; Zhou ZQ; Tang Y; Xia JC
    J Cancer; 2018; 9(19):3447-3455. PubMed ID: 30310501
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of weekly versus triweekly cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma: A meta-analysis.
    Chen L; Li YC; Hu M; Zhao SJ; Yang QW
    Medicine (Baltimore); 2022 Dec; 101(52):e31842. PubMed ID: 36596073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
    Liao JF; Zhang Q; Du XJ; Lan M; Liu S; Xia YF; Cai XY; Luo W
    Cancer Commun (Lond); 2019 Jun; 39(1):40. PubMed ID: 31248459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy.
    Li X; Li L; Sun R; Gao J; Li Z; Xue Y; Zhu L; Xu T; Sun C; Xi Y; Xiong W
    Eur J Med Res; 2023 Oct; 28(1):399. PubMed ID: 37794519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).
    Lee JY; Sun JM; Oh DR; Lim SH; Goo J; Lee SH; Kim SB; Park KU; Kim HK; Hong DS; Kim JS; Kim SG; Yi SY; Yun HJ; Hyun MS; Kim HJ; Jung SH; Park K; Ahn YC; Ahn MJ
    Radiother Oncol; 2016 Feb; 118(2):244-50. PubMed ID: 26705681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma.
    Wang K; Dong J; He S; Wang X; Jiang C; Hu P; Guo J; Cai X; Wang X
    BMC Cancer; 2019 May; 19(1):482. PubMed ID: 31117967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of weekly versus 3-weekly cisplatin during concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study.
    Meng DF; Sun R; Peng LX; Huang YS; Yang Q; Luo DH; Hu WH; Xie FY; Luo W; Zhao C; Guo L; Mai HQ; Chen MY; Xie P; Zheng LS; Yang JP; Mei Y; Qiang YY; Xu L; Li CZ; Huang BJ; Qian CN; Sun R
    J Cancer; 2018; 9(1):92-99. PubMed ID: 29290773
    [No Abstract]   [Full Text] [Related]  

  • 9. Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy for nasopharyngeal carcinoma: a systematic review and pooled analysis.
    Tang J; Zou GR; Li XW; Su Z; Cao XL; Wang BC
    J Cancer; 2021; 12(20):6209-6215. PubMed ID: 34539894
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
    Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
    Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
    Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.
    Li WF; Li YQ; Chen L; Zhang Y; Guo R; Zhang F; Peng H; Sun Y; Ma J
    BMC Cancer; 2015 Oct; 15():810. PubMed ID: 26506820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of weekly versus triweekly cisplatin treatment concomitant with radiotherapy for locally advanced nasopharyngeal carcinoma: A systematic review and pooled analysis.
    Tian X; Zhu Q; Zhang Z
    Front Pharmacol; 2022; 13():999027. PubMed ID: 36686714
    [No Abstract]   [Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy with Fluorouracil plus Nedaplatin or Cisplatin for Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Study.
    Liu T; Sun Q; Chen J; Li B; Qin W; Wang F; Ye Z; Hu F
    J Cancer; 2018; 9(20):3676-3682. PubMed ID: 30405836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
    Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.